NASDAQ · RCKT
Rocket Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RCKT: Nov 5, 2026
Rocket Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.39. The reported EPS for the same quarter last year was $-0.45.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.39 | $-0.30 | $-0.43 | 4 |
| Dec 2026 | $-0.39 | $-0.24 | $-0.55 | 3 |
| Mar 2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Jun 2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · Zacks · RTTNews- Fintel · Oct 8, 12:30 PM EDTGoldman Sachs Upgrades Rocket Pharmaceuticals to Neutral from SellFintel reports that on October 8, 2026, Goldman Sachs upgraded their outlook for Rocket Pharmaceuticals (NASDAQGM:RCKT) (DB:9IP1) from Sell to Neutral. This action follows a prior decision on March 2, 2026, when the firm maintained its Sell rating on the stock.On October 7, 2026,
- MarketBeat · Oct 6, 10:02 PM EDTRocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset3 Small-Cap Stocks That Are Ready to Rocket HigherRocket Pharmaceuticals (NASDAQ:RCKT) outlined updated clinical, regulatory and commercial plans for its investigational gene therapy RP-A501 in Danon disease, reporting longer-term Phase I findings, preliminary Phase II observatio
- Fintel · Sep 16, 10:19 PM EDTNeedham Upgrades Rocket Pharmaceuticals to Buy from HoldFintel reports that on September 16, 2026, Needham upgraded their outlook for Rocket Pharmaceuticals (NASDAQGM:RCKT) from Hold to Buy.Rocket Pharmaceuticals, Inc., headquartered in the United States, is at the forefront of the biotechnological industry, specializing in the develo
- Zacks · Sep 16, 10:56 AM EDTRCKT Aligns With FDA on Completing Phase II Study in Danon DiseaseRocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
- RTTNews · Sep 15, 7:51 AM EDTRocket Gets FDA Nod To Advance RP-A501 Phase 2 Trial In Danon Disease; Stock Up(RTTNews) – Rocket Pharmaceuticals, Inc. (RCKT), a commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, announced alignment with the U.S. FDA on continued enrollment and dosing, as well as key elements of the pivotal Phase 2
- Zacks · Sep 11, 11:30 AM EDTAllogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Sep 10, 11:30 AM EDTWhy Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Sep 9, 11:30 AM EDTRocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Aug 11, 2:21 PM EDTRocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in FocusRCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
- Zacks · May 11, 11:50 AM EDTRCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in FocusRocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
- Zacks · Mar 30, 12:16 PM EDTRCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseRocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.
- RTTNews · Mar 30, 11:47 AM EDTWedbush Reaffirms Rocket Pharma At Outperform With $16 Price Target(RTTNews) – Wedbush on Monday reiterated its Outperform rating and 12-month price target of $16 for Rocket Pharmaceuticals(RCKT).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Rocket Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.